EHT

Synergistic neuroprotection by coffee components eicosanoyl-5-hydroxytryptamide and caffeine in models of Parkinson’s disease and DLB Run Yan, Jie Zhang, Hye-Jin Park, Eun S. Park, Stephanie Oh, Haiyan Zheng, Eunsung Junn, Michael Voronkov, Jeffry B. Stock, and M. Maral Mouradian (2018)

 

Eicosanoyl-5-hydroxytryptamide (EHT) prevents Alzheimer’s disease-related cognitive and electrophysiological impairments in mice exposed to elevated concentrations of oligomeric beta-amyloid. Kesava Asam1,2, Agnieszka Staniszewski1,2, Hong Zhang1,2, Scott L. Melideo3, Adolfo Mazzeo1,2, Michael Voronkov4, Kristen L. Huber4, Eduardo Pe ´rez4, Maxwell Stock4, Jeffry B. Stock3,4, Ottavio Arancio1,2,5, Russell E. Nicholls1,2* (2017)

 

Neuroprotective and Anti-inflammatory Properties of a Coffee Component in the MPTP Model of Parkinson’s Disease.Kang-Woo Lee, Joo-Young Im, Jong-Min Woo, Hilary Grosso, Yoon-Seong Kim, Ana Clara Cristovao, Patricia K. Sonsalla, David S. Schuster, Marla M. Jalbut, Jose R. Fernandez, Michael Voronkov, Eunsung Junn, Steven P. Braithwaite, Jeffry B. Stock, and M. Maral Mouradian, Neurotherapeutics. 2013

 

Therapeutic benefits of a component of coffee in a rat model of Alzheimer disease. Neurobiology of Aging, 2014.   Basurto-Islas, G., Blanchard, J., Tung, Y. C., Fernandez, J. R., Voronkov, M., Stock, M., Zhang, S., Stock, JB., Iqbal, K. (2014). 

 

Enhanced Phosphatase Activity Attenuates α-Synucleinopathy in a Mouse Model. Neurobiology of Disease, 2011. Lee KW, Chen W, Junn E, Im JY, Grosso H, Sonsalla PK, Feng X, Ray N, Fernandez JR, Chao Y, Masliah E, Voronkov M, Braithwaite SP, Stock JB, Mouradian MM.

Previous
Previous

SIG-1191™

Next
Next

SIG-1273™